• Overview
  • Eligibility
  • More info
  • Locations

Extended Release/Long Acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) Medical Examiner Surveillance Monitoring Protocol (NCT02897414)

In April 2011, the U.S. Food and Drug Administration (FDA) determined that a class-wide risk evaluation and mitigation strategy (REMS) for all extended-release (ER) and long-acting (LA) opioid medications was necessary to support national efforts to reduce serious adverse outcomes resulting from opioid abuse. This study will evaluate trends before and after the ER/LA REMS implementation for changes in mortality rates associated with prescription opioids utilizing state medical examiner databases from multiple states. Databases from 2005 through the most recent year available will be obtained.
  • Other: Surveillance of state medical examiner databases
    Ages eligible for Study
    all
    Genders eligible for Study
    All
    Accepts Healthy Volunteers
    Status:
    enrolling by invitation
    Type:
    Observational
    Phase:
    -
    Start:
    01 January, 0001
    Updated:
    06 September, 2016
    Participants:
    13015
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!